Dec 16 (Reuters) - Basilea Pharmaceutica AG Allschwil BSLN.S:
BASILEA ANNOUNCES AGREEMENT WITH INNOVIVA SPECIALTY THERAPEUTICS FOR THE COMMERCIALIZATION OF ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE) IN THE UNITED STATES
BASILEA PHARMACEUTICA AG ALLSCHWIL - TO RECEIVE $4 MILLION UPFRONT PAYMENT, UP TO $223 MILLION IN MILESTONES
Source text: ID:nGNXRFJGH
Further company coverage: BSLN.S
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.